Loading clinical trials...
Loading clinical trials...
Evaluation of Antibody Persistence at 3.5 and 4.5 Years of Age in Healthy Children After Primary Series and Booster Vaccination With Investigational (DTaP-IPV-Hep B-PRP~T) or Infanrix Hexa™ Vaccines in Latin America
Conditions
Interventions
DTaP-IPV-Hep B- PRP~T + Prevenar + Rotarix vaccine
DTaP- IPV-Hep B-PRP~T + Prevenar + Rotarix + Infanrix hexa vaccine
+1 more
Locations
2
Colombia
Cali, Colombia
San José, Costa Rica
Start Date
October 1, 2013
Primary Completion Date
June 1, 2015
Completion Date
December 1, 2015
Last Updated
January 5, 2016
NCT07203755
NCT07112144
NCT06947499
NCT07149454
NCT06258057
NCT06708286
Lead Sponsor
Sanofi Pasteur, a Sanofi Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions